MedPath

Grape Juice and Dermatitis in Breast Cancer

Not Applicable
Conditions
Breast Cancer
Interventions
Other: control
Dietary Supplement: grape juice
Registration Number
NCT04890184
Lead Sponsor
National Nutrition and Food Technology Institute
Brief Summary

This study aimed to investigate the effect of grape juice on acute radiation dermatitis in breast cancer (BC) patients undergoing radiotherapy (RT). 50 eligible BC patients will randomly assign to consume 100 gr of grape juice per day during and 1 week after RT or with no intervention (control group). The radiation dermatitis will be assessed weekly according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales.

Detailed Description

Dietary intake of patients will be examined by expert dietitians at baseline and end of RT using the average of three-day 24-hour recalls. Weight (kg), body fat percentage, skeletal muscle percentage and visceral fat level will be measured using the OMRON Body Composition Monitor and Scale.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
50
Inclusion Criteria
  • women with Brest Cancer undergoing adjutant Radiation therapy
Exclusion Criteria
  • previous history of RT, MRM,
  • concomitant presence of two or more malignant tumors
  • metastasis to other areas
  • allergy or intolerance to tahini
  • skin diseases and wounds
  • severe liver and renal disease
  • autoimmune diseases
  • pregnant and lactating women
  • those who treated with hypo fraction RT

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
controlcontrolno dietary intervention
grape juicegrape juice100 g of grape juice daily
Primary Outcome Measures
NameTimeMethod
severity of dermatitis4 weeks

Change from Baseline severity at 4 weeks. The radiation dermatitis will be assessed according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath